Medtronic, Novartis and SinoPharm are among the investors in a series B round for Semma Therapeutics, which is working on a treatment for patients suffering from diabetes.
US-based diabetes treatment developer Semma Therapeutics closed a $114m series B round today that included medical device manufacturer Medtronic and pharmaceutical firms Novartis and SinoPharm.
SinoPharm contributed cash through its corporate venturing arm SinoPharm Capital. The round also featured 6 Dimensions Capital, an investment firm established by pharmaceutical firm WuXi AppTec’s WuXi Healthcare Ventures unit and Frontline Bioventures.
Eight Roads Ventures and Cowen Healthcare Investments co-led the round, which further included MPM Capital, F-Prime Capital Partners, Arch Venture Partners, Ori…
